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Abstract.
INTRODUCTION: COVID-19 is a systemic infection with a significant impact on coagulation which manifests in throm-
boembolism. There is an unknown relationship of which coagulation profile parameter at presentation has an association
with poor outcome in COVID-19.
OBJECTIVE: This meta-analysis aimed to determine the relationship between fibrinogen and FDP with poor outcome in
COVID-19 patients.
METHODS: A systematic search of all observational studies or trials involving adult patients with COVID-19 that had any
data fibrinogen or FDP on admission was carried out using the PubMed, Science Direct, Scopus, ProQuest, and MedRxiv
databases. We assessed the methodological quality assessment using the NIH Quality Assessment Tool. We performed
random-effects inverse-variance weighting analysis using mean difference (MD).
RESULTS: A total of 17 studies (1,654 patients) were included in this meta-analysis. It revealed a higher mean of fibrinogen
levels on admission in patients with severe case compared to those with non-severe case (MD = 0.69, [95% CI: 0.44 to 0.94],
p < 0.05; I2 = 72%, p < 0.05). Non-survivor group had a pooled higher mean difference of fibrinogen values on admission
(MD = 0.48 [95% CI: 0.13 to 0.83], p < 0.05; I2 = 38%, p = 0.18). Higher FDP on admission was found in poor outcome
(composite of severity, critically ill, and mortality) compared to good outcome (4 studies, MD = 4.84 [95% CI: 0.75 to 8.93],
p < 0.05; I2 = 86%, p < 0.05).
CONCLUSION: Elevated fibrinogen and FDP level on admission were associated with an increase risk of poor outcome in
COVID-19 patients.
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1. Introduction
COVID-19 is a systemic infection with a significant impact on coagulation which manifests in throm-
boembolism. Furthermore, disseminated intravascular coagulopathy appeared in most of the deaths
[1]. At the late stages of COVID-19, a common coagulation activation and secondary hyperfibrinolysis
condition occurred and accompanied with elevated levels of fibrin-related markers (D-dimer and fibrin
degradation product [FDP]) and low fibrinogen level [2].
At initial presentation of coagulopathy, patients with COVID-19 presents with a prominent eleva-
tion of fibrinogen and FDP [3]. Some studies showed that significant coagulopathy was present in
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COVID-19 patients with elevated fibrinogen at presentation [4]. Nevertheless, there is an unknown
relationship of which coagulation profile parameter at presentation has an association with severity and
mortality in COVID-19. This meta-analysis aimed to determine the relationship between fibrinogen
and FDP with poor outcome in COVID-19 patients.
2. Methods
This study in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) [5]. We selected all observational studies involving adult patients with
COVID-19 that had any fibrinogen and FDP data for comparison severe vs. non-severe, and survivor
vs. non-survivor. We excluded any study that had missing required data, fibrinogen and FDP data not
collected on admission, and data not presented in numerical variables.
A systematic search of the literature was carried out on May 15, 2020, after receiving approval from
the Institutional Review Board. Five different databases (PubMed, Science Direct, Scopus, ProQuest,
and MedRxiv) were used to perform a systematic search of all the literature using the keywords
“intensive” and “laboratory” and “fibrinogen” OR “fibrinogen degradation products OR FDP” and
“COVID-19” or “coronavirus 2019” or “2019-nCoV” or “SARS-CoV-2” in the title, abstract, and
medical subject heading (MeSH). Reference lists of the included studies were also screened to identify
additional relevant studies.
Three investigators independently screened and assessed titles and abstracts before full-text retrieval.
The full papers that potentially met the inclusion/exclusion criteria were reviewed by the two authors
for final inclusion. Subsequently, two investigators extracted the data, including authors, year of publi-
cation, location, study design, peer-reviewed publication status, severity measurement, and fibrinogen
and FDP level in each comparison group. All extracted data were recorded with a dedicated form on
an Excel spreadsheet.
The primary outcome in our meta-analysis was fibrinogen on admission based on severity. All
definition of severity was used in this meta-analysis. If the study categorized severity into 3 or 4
groups, we combined the data between mild and moderate groups into one group as non-severe; severe
and critical group into one group as severe. The average of their mean and standard deviation was
calculated using the formula in Table 7.7.a of the Cochrane Handbook [6]. The secondary outcomes
were fibrinogen on admission based on mortality and FDP level on admission based on composite
poor outcome that comprised of severity and mortality.
Two authors independently assessed the methodological quality assessment using the NIH Quality
Assessment Tool for Observational Cohort and Cross-Sectional Studies [7]. Publication bias assessed
using visual inspection of funnel plots and Egger’s regression test [8]. We conducted the meta-analysis
using mean difference (MD) for fibrinogen and FDP values. Mean and standard deviation were extrapo-
lated from sample size, median, and interquartile range (IQR), according to Wan et al. [9]. We employed
a random-effects and inverse-variance weighting using Review Manager (RevMan v5.3 2014). We per-
formed subgroup analysis based on study design. Sensitivity analysis was done using leave-one-out
method to assess the cause of heterogeneity. We evaluated between and within-study heterogeneity
using the I2 statistic.
3. Results
Initial search provided 161 records from the PUBMED, 100 records from Science Direct, 107
records from ProQuest, 82 records from Scopus database, 111 records from Medxriv database, and
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Fig. 1. Study flow chart (as per PRISMA guideline).
36 records from other sources as shown in Fig. 1. After removing the duplicate and screening of title
and abstracts, 106 full texts were then assessed for eligibility. A total of 89 were excluded because
of incorrect patient population (n = 7), unavailability of data on fibrinogen or fibrin degradation prod-
uct (n = 63), and irrelevant outcome (n = 19). Totally, we included 17 studies (1,654 patients) for
analysis.
The baseline characteristics of the included studies are presented in Table 1. Fifteen studies were
retrospective, and two studies were prospective observational. Ten studies have already been undergone
peer-review [2, 10–18]. Most of the studies classified the severity according to the National Health
Commission of People’s Republic of China.
We assessed all studies’ quality based on NHLBI quality assessment resulting in good and fair
methodology qualities in all included studies (Table 1). None of the studies was considered to be
seriously flawed. The analyses were rigorous, and the conclusions drawn by the studies were credible.
However, most studies did not assess exposure prior to outcome measurement and might not have
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Fig. 2. Funnel plot shows no publication bias for (A) fibrinogen and severity [p = 0.154], but there are publication biases for
(B) fibrinogen and mortality, and (C) fibrin degradation product and composite poor outcomes in patients with COVID-19.
The Egger’s test showed there was no publication bias for fibrinogen in severity outcome (p = 0.154).
We did not conduct Egger’s test for other outcomes because there were less than ten included studies.
Figure 2 shows that all funnel plots showed an asymmetrical appearance indicating publication bias
in fibrinogen for mortality outcome and FDP for composite poor outcomes.
Random-effects meta-analysis revealed a higher mean of fibrinogen level on admission in patients
with severe case compared to those with non-severe case as shown in Fig. 3A (12 studies, MD = 0.69,
[95% CI: 0.44 to 0.94], p < 0.05; I2 = 72%, p < 0.05). Subgroup analysis based on study design showed
no difference result in prospective design subgroup. Sensitivity analysis using leave-one-out method
showed that removal of Shi et al. [19]. reduced the heterogeneity with similar result (MD = 0.75, [95%
CI: 0.47 to 1.04], p < 0.05; I2 = 64%, p < 0.05).
Non-survivor group had a pooled higher mean difference of fibrinogen level on admission than
survivor group as shown in Fig. 3B (4 studies, MD = 0.48 [95% CI: 0.13 to 0.83], p < 0.05; I2 = 38%,
p = 0.18). There was no substantial heterogeneity found across the studies. We did not perform subgroup
analysis based on study design because all included studies were retrospective observational.
Higher FDP on admission was found in poor outcome (composite of severity, critically ill, and
mortality) compared to good outcome as shown in Fig. 3C (4 studies, MD = 4.84 [95% CI: 0.75 to
8.93], p < 0.05; I2 = 86%, p < 0.05). Subgroup analysis of retrospective design showed similar results.
Sensitivity analysis showed that removal of Zheng et al. [14]. reduced the heterogeneity with similar
result (MD = 6.49, [95% CI: 1.45 to 11.53], p < 0.05; I2 = 81%, p < 0.05).
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Fig. 3. (A) Forest plot of fibrinogen for severity; (B) Forest plot of fibrinogen for mortality; (C) Forest plot of fibrinogen
degradation product for poor outcome.
4. Discussion
This meta-analysis showed that high fibrinogen levels on admission were significantly associated
with severity and mortality. In addition, elevated FDP was significantly associated with composite poor
outcome. Our results are in line with previous studies about the association between poor prognosis
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of COVID-19 and coagulation profile as appeared in early reports from China [3].
One study by Tang et al. reported that non-survivors had higher fibrinogen and FDP level than
survivors on early stage of disease. In the late course of the disease, non-survivors had a significantly
lower level of fibrinogen than survivors [2]. Another study reported that COVID-19 patient had high
level of fibrinogen while DIC patient had low fibrinogen level [26].
The normal plasma concentration of fibrinogen is between 2 and 4 g/l; however, this concentration
can rapidly increase under pathological conditions such as injury, infection, or inflammation [27]. Viral
infections may induce severe complications such as acute respiratory distress syndrome and multi-
organ failure which are often accompanied by hypercoagulation and DIC [28, 29]. The laboratory
features of DIC vary widely depending on the stage encountered. In early DIC, there is compensated
activation of the hemostatic system, however with progression to decompensated hemostatic activa-
tion, characteristic findings are observed. Fibrinogen levels vary; however, in advanced stages of DIC,
fibrinogen levels decrease [26]. The exact mechanism for coagulopathy in COVID-19 is not yet iden-
tified. COVID-19 is able to directly attack vascular endothelial cells expressing high levels of ACE2,
leading to abnormal coagulation and sepsis. The virus enters endothelial cells by endocytosis via the
binding of its spike glycoprotein to a cellular receptor which facilitates viral attachment to the surface
of target cells [30, 31].
The prevalence of VTE, particularly in critically ill/severe patients suffering from COVID-19, was
reported as much as 25–27% [32]. VTE is often associated with plasma hypercoagulability. An elevated
plasma fibrinogen level significantly increases the risk of VTE. These findings suggest hyperfibrino-
genemia is not merely a biomarker of thrombotic risk, but is causative in the etiology of venous
thrombosis [33].
Hyperfibrinolysis was present in 97% of COVID-19 patients [34]. Fibrin and FDP are formed during
intravascular clotting [35]. A study observed an increase of activated plasmin and fibrinolytic activity
in COVID-19 patients which resulted in the elevated FDP [36]. At late stages of COVID-19, FDP were
reported to be moderately or markedly elevated in all COVID-19 deaths [37].
Lung computed tomography (CT) scan shows an important role in the detection of thromboem-
bolic events in COVID-19. Abdominal microcirculatory disorders, as well as central or peripheral
pulmonary embolism was also found in severe cases of COVID-19. As the disease worsened, the labo-
ratory parameter of fibrinogen was increased to some varying degree, and multiple lesions in CT scan
were progressively noticed [38, 39]. Imaging modality which is greatly beneficial in detecting throm-
botic events occurrence in these cases in addition to lung CT scan, is contrast-enhanced ultrasound
(CEUS). Peripherally accentuated consolidation with irregular hyperemia was found in the CEUS and
also in the CT examination in cases of pulmonary thrombus embolism [40]. CEUS can dynamically
record the mesenteric arterial and venous blood flow, thus enabling us to quickly rule out abdominal
infarction [41].
Our meta-analysis suggests that elevated fibrinogen on admission can also be a marker of poor
prognosis in patients with COVID-19. During a pandemic, risk stratification in triage is necessary,
and fibrinogen levels can be one of potential indicators of high-risk patients. While D-dimer level is
often used to aid the decision of starting an anticoagulant, fibrinogen level might direct the physician
to stop anticoagulation. It should be noted that, like all cases of DIC, patients may progress to a
hypercoagulable state when fibrinogen levels begin to decrease. At this point, stopping anticoagulation
should be considered.
To the best of authors knowledge, our meta-analysis comprising of 17 studies is the largest meta-
analysis evaluating the prognostic role of fibrinogen on admission in COVID-19. However, several
limitations should be noted in our study. First, there was substantial heterogeneity across studies. Most
of included studies were retrospective with a relatively small sample size. Second, the presence of
publication bias. The analysis of this study was performed during pandemic; many areas affected by
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COVID-19 have not published the data yet. Most of the studies included were from mainland China.
The ethnic and geographical differences might distort the results.
5. Conclusions
Our meta-analysis demonstrated that elevated fibrinogen and fibrin degradation products on admis-
sion were associated with an increased risk of poor outcome in COVID-19 patients.
Data availability
The data supporting this meta-analysis are from previously reported studies and datasets, which have
been cited.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be considered as a potential conflict of interests.
Acknowledgments
This work did not receive specific funding, but was performed as part of Johanes Nugroho employ-
ment at the Department of Cardiology and Vascular Medicine, Universitas Airlangga/Dr. Soetomo
General Hospital, East Java, Indonesia.
References
[1] Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS- CoV-1,
MERS-CoV and lessons from the past 2020. J Clin Virol. 2020;127:104362.
[2] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with
novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7.
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